

REMARKS

Upon entry of the amendment, claims 1-6 and 19-23 will be pending. The specification has been amended to correct the priority statement, make reference to the sequence listing that was filed with the parent application, to insert SEQ ID NOs into the specification to correspond to one sequence in the originally filed application, and to make the abstract better reflect the invention of the instant application. Support for the amendment to the abstract can be found throughout the application, specifically in the abstract as filed, on page 94, lines 33-35, page 95, line 9, and in Examples 30-33. An amended electronic version of the Sequence Listing has also been filed.

The Applicants submit that these amendments constitute no new matter.

FEES

It is believed that no fee is due with this amendment. However, if a fee is due, the Commissioner is hereby authorized to charge the Deposit Account 50-0252 referencing case number ISIS-0852US.

CONCLUSIONS

In view of these amendments and remarks, the Applicants believe that the case is now in proper form for examination. A prompt office action on the merits of the case is requested.

Respectfully submitted,

Date: Dec 5, 2005



Colleen J McKiernan, Ph.D.
Agent for Applicant
Reg. No. 48,570

IISIS PHARMACEUTICALS, INC.
1896 Rutherford Road
Carlsbad, CA 92003
Phone: 760-603-2722
Fax: 760-603-3820